All In Biotech

Drug Trial Radar · NCT00209430

Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Coronary Angiography

GEHC Has Decided Not to Provide This Detail But Will Rely on the Brief Title.

Last checked: Nov 19, 2026Latest source record: Oct 31, 2007 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 408 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

408

Actual

Start

Aug 2005

Primary completion

Not stated

Sponsor

Lead sponsor
GE HealthcareIndustry
Sponsor type
Industry
First posted
Sep 21, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Diagnostic
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to evaluate and compare the effects on kidney function of two contrast media, the iso-osmolar iodixanol and the low-osmolar iopamidol in patients at risk of kidney damage associated with the injection of contrast media. A standard hydration procedure, based on available guidelines will be given to all patients to prevent negative effects on the kidneys. Serum creatinine (SCr ) concentrations will be measured before and up to 7 days after contrast media administration to evaluate the effects on renal function.

Conditions

  • Coronary Artery Disease
  • Renal Impairment

Interventions

  • Iodixanol 320 mgI/mLDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Peak increase in SCr
  2. Incidence of contrast media-induced nephropathy from baseline up to day 3.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Amersham Health S.A

    Solna, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.